Background -The neutrophil elastase inhibitor, secretory leucocyte protease inhibitor (SLPI), is a potential therapeutic tool in inflammatory lung diseases such as cystic fibrosis and pulmonary emphysema. The distribution and disappearance in the lung of aerosolised recombinant SLPI (rSLPI) was investigated in healthy humans and in patients with cystic fibrosis or a,-antitrypsin-associated emphysema. Methods -To distinguish aerosolised rSLPI from endogenous SLPI the recombinant inhibitor was radiolabelled with 99m-technetium (99'Tc) pertechnetate. Distribution and disappearance of aerosolised 99'Tc-rSLPI in the lungs were studied by gamma radiation imaging.
Human secretory leucocyte protease inhibitor (SLPI), also called antileucoprotease, is a potent inhibitor of neutrophil elastase. 1 '2 It is produced in serous cells of submucosal glands of the bronchi and trachea as well as in nonciliated bronchiolar epithelial cells.3 The secretion of SLPI occurs at a steady level, irrespective of the presence of inflammation in the airways.4 Besides secretion of SLPI into the lumen of the airways, it is also found in close contact with elastin fibres in lung interstitium.
This suggests that SLPI also diffuses into lung interstitium. In vitro studies with cultured bronchial gland cells have shown that secretory proteins such as SLPI and lysozyme are secreted at both apical and basal sites of the cells, suggesting that these cells have vectorial delivery. 6 Proteinases including neutrophil elastase and cathepsin G are released from neutrophils during bacterial infection in the human airways in cystic fibrosis or in chronic obstructive pulmonary disease (COPD) . Treatment with SLPI may improve bacterial phagocytosis by neutrophils due to protection of cell surface receptors and opsonins against elastase-mediated degradation.910 Moreover, it may reduce the production of mucins, since free elastase is one of the most potent stimuli of mucin production in the airways.11 SLPI is now available by recombinant DNA technology."2 It is not efficient to administer rSLPI orally or intravenously to humans because the compound is rapidly excreted by the kidneys.'3 Aerosol administration may be an attractive route for clinical application. Studies in sheep have shown that aerosol administration of rSLPI significantly augments rSLPI levels in epithelial lining fluid.'4 However, these studies also showed that the levels in lymphatic fluid of the lung, which can be regarded as representative of interstitial fluid, were 300-400 times lower than levels in the bronchial lumen. The low concentration of rSLPI in the lymph may be explained by its selective association with elastin fibres present in lung interstitium due to the cationic charge of SLPI.' Not much is known about the half life or even the production rate of endogenous SLPI in a human bronchial tree. Some studies have shown that SLPI is present in bronchoalveolar lavage (BAL) fluid and in sputum in nanomolar and millimolar concentrations, respectively.516 Measurements of aerosolised rSLPI in BAL fluid by immunochemical methods are difficult to interpret because of the presence of endogenous SLPI. One approach to circumvent this problem is to use radiolabelled rSLPI. The aim of the present study was to determine the distribution and half life of aerosolised rSLPI labelled with 99m-technetium (99mTc) in healthy individuals and in patients with cystic fibrosis or pulmonary emphysema associated with cxl-antitrypsin deficiency of ZZ phenotype.
Methods

VALIDATION OF THE LABELLING METHOD
Human rSLPI was supplied by Synergen (Boulder, Colorado, USA) in vials of 100 mg protein.
Each vial was dissolved in 5 ml saline and rSLPI rSLPI solution was incubated at room temperature with sodium 99mTc pertechnetate and reducing agents such as 0 97ng/ml SnCl,, 116 ng/ml DTPA, and 97 ng/ml KBH4 for 20 minutes. Labelling efficiency was 96 (1) % (n=5) as assessed by reversed phase chromatography with an RP-1 8 lichrosorb column (Whatmann, Middleburg, Netherlands). After labelling, elastase inhibitory capacity and immunoreactivity were assayed as previously described. ' 16 To test whether the radiolabel was still attached to the protein while present in the lung, 24 Golden Syrian hamsters each received 20 ig rSLPI labelled with 02 MBq of 99mTc in a volume of 200 ,ul saline by the intratracheal route. In a period of 24 hours at eight different times, three hamsters were killed. The lungs were lavaged twice with 2 5 ml saline. 24 hours after inhalation. The disappearance of activity was measured in the total right lung and in a region of interest (ROI) in the right hilar region. The Pariboy chamber, tubing, and filter were counted in an identical fashion following aerosol delivery.
When the study with the five healthy volunteers was completed, five patients with emphysema associated with hereditary oclantitrypsin deficiency and three patients with cystic fibrosis were tested in a similar way. Patients were included in the study when their forced expiratory flow in one second was between 30% and 50% of predicted, measured after salbutamol inhalation. They inhaled the aerosol while breathing at tidal volume seated on a stool, with no specific medication used shortly before the aerosol inhalation started. The disappearance rate of 99mTc-rSLPI was measured in the total right lung and right hilar region.
To study further bronchial and tracheal disappearance we measured the activity of 99mTc-rSLPI over the first two hours after aerosol inhalation by continuous data registration with the gamma camera in one healthy volunteer and one patient with emphysema of ZZ phenotype in the supine position. Both individuals inhaled the aerosol as described above. Disappearance was measured in the total right lung. Disappearance of activity in the hilus and trachea was counted in small ROI over the right hilus and trachea, respectively.
STATISTICAL ANALYSIS
To analyse the mode ofdisappearance of 99mTc-rSLPI from the lungs a non-linear regression procedure was applied using an SPSS program (SPSS Inc, Chicago, USA). Monoexponential and biexponential curve fitting was calculated by y=A.e-Bx and y=A.e-Bx+C.e-Dx, respectively. In biexponential disappearance rapid phase half life was calculated as ln2/B and slow phase as ln2/D, respectively. The percentage oftotal deposition in the rapid phase was calculated as (A/(A + C)) x 100% and in the slow phase as (C/(A + C)) x 100%, respectively. Curves were considered to be biexponential if, in a semilogarithmic plot, a biexponential graph showed a better fit than the monoexponential one and the corresponding sum ofsquare differences differed substantially.
Results
VALIDATION OF LABELLING METHOD
Elastase inhibitory capacity and immunoreactivity in an ELISA of rSLPI labelled with 99mTc were not different from unlabelled rSLPI (data not shown). When a solution of 99mTc-rSLPI was instilled in the trachea of hamsters the half life in BAL fluid was about two hours. As can be seen in fig 1 the disappearance rate assessed by 99mTc activity (y axis left) of the instilled solution did not differ from the rate as assayed by ELISA (y axis right). Figure 2 shows that lung homogenate of lungs instilled with 99mTc-rSLPI revealed similar disappearance rates to those seen in fig 1. These results indicate that "mTc-rSLPI is quite stable while present in the hamster lung. The distribution ofthe radiolabel in the lungs of patients with emphysema and cystic fibrosis was patchy (fig 3B and 3C) . Emphysematous areas in the lower lobes, as observed on diagnostic ventilation scintigrams with 8mKr gas (data not shown), were poorly filled with the SLPI aerosol ( fig 3B) . In patients with cystic fibrosis, hot spots were observed in hilar regions and in peripheral parts of both lungs ( fig 3C) . The disappearance of rSLPI from the right lung of patients with emphysema and cystic fibrosis was biphasic in both patient groups. None of the curves fitted into a monoexponential plot. The rapid disappearance of rSLPI from the total right lung in patients with emphysema had a mean (SE) 4). More than half of the deposited rSLPI disappeared in the slow phase of the curve. In patients with cystic fibrosis the rapid phase half life of rSLPI in the total right lung was 2-33 (0 15) hours while the slow half life was more than 42 hours. The rapid phase of disappearance represented 38 (9 8)% of all rSLPI deposited in the lung. In order to investigate further bronchial and tracheal movement of the radiolabel in the rapid phase of ++mTc-rSLPI disappearance we measured ++mTc activity in one healthy volunteer during two hours of continuous recording. 40% of the deposited activity disappeared in the first 20 minutes after inhalation ( fig 5A) . The activity in a small ROI in the hilar region declined by 80% in 10 minutes and remained stable at about 20% during the next 110 minutes ( fig 5B) . In an ROI in the trachea 99mTc-rSLPI passed in the first 60 minutes only ( fig  5C) . The patient did not cough during the recording period.
Discussion
This study has shown that deposition of aerosolised rSLPI occurs in well ventilated areas of the human lung and that the disappearance in patients with bronchial obstruction is biphasic with a rapid half life shorter than five hours and a slow half life longer than 24 hours. We have established that the radiolabel remained attached to the protein while in the airways because the ratio of measured rSLPI levels and 99mTc counts in BAL fluid in hamsters did not differ from the ratio of the instilled material.
The aerosol was generated continuously in the Pariboy because the trigger was taped to reduce the radiation burden for the volunteers. There were no valves in the tubing system connected to the patient and the filter. This procedure most probably caused the high deposition of 99mTc-rSLPI in the filter. The ratio between deposition in the lung and the oropharynx plus stomach is similar to results obtained with other aerosol delivery systems. '819 This indicates that breathing at tidal volume, sitting on a stool, under the experimental conditions as described, resulted in efficient deposition of rSLPI in both healthy volunteers and patients with COPD. Within the lung, several factors may influence the site of particle deposition.20 Increased central deposition by impaction occurs with increasing inspiratory flow rate. A breath-hold of up to 10 seconds after inhalation enhances drug deposition by allowing longer for sedimentational de- position.20 Also, a decrease in airway calibre may increase deposition in the central airways by increasing turbulent airflow. In fact, the latter deposition pattern was observed in our patients with emphysema and cystic fibrosis. Distribution was patchy and hot spots were seen in several fields of the lung. In patients with emphysema these hot spots may represent bronchi being obstructed by extrabronchial pressure from bullae in emphysema. In patients with cystic fibrosis the spots may be caused by widened carinae of narrowed bronchi due to mucosal inflammation or by bronchi obstructed with mucus plugs. The Pariboy jet nebuliser is frequently used for aerosolisation of bronchodilating and mucolytic drugs. We found it outside the scope of this study to measure particle size of the SLPI aerosol, given the numerous other variables which may be responsible for the results we obtained. We have previously shown that the Pariboy does not produce particle sizes which are very different from other jet nebulisers. '8 In emphysematous patients deposition of rSLPI coincided with ventilated areas seen on a 8mKr ventilation scintigram (data not shown).
This deposition pattern of rSLPI may be efficacious in protecting normal alveolar architecture from further tissue destruction by proteases. Areas which have been destroyed and are poorly ventilated need no further protection by rSLPI, since the lung has no capacity to regenerate new alveoli. In patients with cystic fibrosis it is desirable to deposit rSLPI in well ventilated areas for protection of lung tissue against proteases, but it is also needed in poorly ventilated areas which are most likely to contain bronchial walls infiltrated with neutrophils. A recent study in patients with cystic fibrosis showed that active neutrophil-derived elastase levels in BAL fluid were still present after treatment with an aerosol of rSLPI at a dose of 100mg twice daily for seven days.2' These results were obtained by analysing BAL fluid before and after treatment. In patients with cystic fibrosis BAL fluid probably represents a mixture of fluid from well and poorly ventilated areas. Thus the observed patchy deposition of rSLPI seen in fig 3C may 
